Metagenomi Therapeutics Inc (MGX): Hedge Fund Ownership & Smart Money Signals (Q1 2026)

Q: Is it too late to buy Metagenomi Therapeutics Inc (MGX) following the 2026 Q1 hedge fund 13F filings?

As of today, MGX has moved -9.9% since the 2026 Q1 13F filing date (May 15, 2026), compared to +3.9% for the XLV sector ETF — an outperformance of -13.8%. Since the quarter end (March 31, 2026), MGX gained -11.9% vs +2.8% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Metagenomi Therapeutics Inc (MGX)

46 + Investors. Track Smart Money conviction in MGX. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — MGX

Based on 46 hedge funds · latest filing: 2026 Q1 · updated quarterly

📉

Selling streak — 4 quarters in a row

last 6Q

For 4 consecutive quarters, more hedge funds reduced or closed their MGX positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

🔻

Below peak — only 60% of 3.0Y high

60% of all-time peak

Only 46 funds hold MGX today versus a peak of 77 funds at 2025 Q1 — just 60% of the maximum. Low institutional ownership can mean the stock is out of favor, but it also means there's a large pool of potential buyers if sentiment turns.

📉

Outflows — 40% fewer funds vs a year ago

fund count last 6Q

31 fewer hedge funds hold MGX compared to a year ago (-40% decline). When institutions consistently reduce their exposure, it's worth exploring the underlying fundamental reasons driving them away.

🔴

Heavy selling pressure — only 32% buying

13 buying27 selling

Last quarter: 27 funds sold vs only 13 buyers. This is widespread institutional distribution — not a few funds rebalancing, but a broad exit. High conviction bearish signal.

⚠️

Fewer new buyers each quarter (-6 vs last Q)

new funds entering per quarter

Funds opening this position for the first time: 18 → 10 → 11 → 5. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.

📌

Mixed — 26% long-term, 20% new

■ 26% conviction (2yr+) ■ 54% medium ■ 20% new

Of the 46 current holders: 12 (26%) held >2 years, 25 held 1–2 years, and 9 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

💎

Buying through price weakness — shares -2%, value -18%

Value

-18%

-1%

Last quarter: funds added -2% more shares while total portfolio value only changed -18%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.

⚠️

Saturation — most institutions already know this story

11 → 18 → 10 → 11 → 5 new funds/Q

New funds entering each quarter: 18 → 10 → 11 → 5. Far fewer institutions are entering now vs. a year ago. When the pool of potential new buyers shrinks this fast, future price support from institutional inflows weakens significantly.

📊

Mixed cohorts — 7% veterans, 26% new entrants

■ 7% veterans ■ 67% 1-2yr ■ 26% new

Of 46 current holders: 3 (7%) held 2+ years, 31 held 1–2 years, 12 (26%) entered in the past year. Balanced distribution — some institutional memory, some recent momentum buyers.

📋

Smaller funds dominant — 18% AUM from top-100

18% from top-100 AUM funds

15 of 46 holders rank in the top 100 by AUM, but together hold only 18% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

2.4

out of 10

Low Exit Risk

Exit risk score 2.4/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q1)	Prior (2025 Q4)	Change
Funds Holding	46	54	-14.81%
13F Shares	7M	7M	-1.69%
Total Value	$9M	$11M	-18.24%
New Positions	5	11	-6
Increased Positions	8	13	-5
Closed Positions	13	14	-1
Reduced Positions	14	16	-2
Total Calls	0	0	-
Total Puts	0	0	-
PUT/CALL Ratio	0.0	0.0	Bullish

Metric

All 13F Filers (2026 Q1)

Prior (2025 Q4)

Change

Funds Holding

-14.81%

13F Shares

-1.69%

Total Value

$9M

$11M

-18.24%

New Positions

-6

Increased Positions

-5

Closed Positions

-1

Reduced Positions

-2

Total Calls

Total Puts

PUT/CALL Ratio

0.0

Bullish

Institutional Holders (2026 Q1)

46 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in MGX. Verified SEC 13F-HR filings.

QUARTER:

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 MGX holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Pura Vida Investments, LLC	2.38%	264,391	$354K
2	Peapod Lane Capital LLC	0.56%	516,761	$683K
3	Catalio Capital Management, LP	0.15%	528,993	$709K
4	Resolute Advisors LLC	0.05%	89,944	$121K
5	Fortitude Advisory Group L.L.C.	0.02%	37,190	$50K
6	Bridgeway Capital Management, LLC	0.01%	395,800	$530K
7	Peak Planning Group, LLC	0.00%	12,500	$17K
8	RBF Capital, LLC	0.00%	64,021	$86K
9	Bbr Partners, LLC	0.00%	53,403	$72K
10	Jacobs Levy Equity Management, Inc	0.00%	382,153	$512K
11	Renaissance Technologies LLC	0.00%	787,900	$1.1M
12	XTX Topco Ltd	0.00%	40,582	$54K
13	Two Sigma Advisers, LP	0.00%	201,300	$326K
14	Two Sigma Investments, LP	0.00%	496,767	$666K
15	Meeder Asset Management Inc	0.00%	5,496	$7K
16	Man Group plc	0.00%	78,636	$105K
17	Millennium Management LLC	0.00%	170,104	$228K
18	Vanguard Fiduciary Trust Co	0.00%	170,174	$228K
19	Wells Fargo & Company/Mn	0.00%	202,138	$271K
20	Marshall Wace, LLP	0.00%	27,521	$37K
21	Vanguard Capital Management LLC	0.00%	1,057,944	$1.4M
22	Hrt Financial LP	0.00%	10,674	$14K
23	Jane Street Group, LLC	0.00%	151,440	$203K
24	Point72 Asset Management, L.P.	0.00%	11,726	$16K
25	US Bancorp \de\	0.00%	4,500	$6K

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Metagenomi Therapeutics Inc (MGX)

What does the Smart Money Trend signal show for MGX?

Selling streak — 4 quarters in a row: For 4 consecutive quarters, more hedge funds reduced or closed their MGX positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for MGX?

Heavy selling pressure — only 32% buying: Last quarter: 27 funds sold vs only 13 buyers. This is widespread institutional distribution — not a few funds rebalancing, but a broad exit. High conviction bearish signal.

What is the fund quality score for MGX holders?

Smaller funds dominant — 18% AUM from top-100: 15 of 46 holders rank in the top 100 by AUM, but together hold only 18% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

How long have hedge funds held MGX?

Mixed — 26% long-term, 20% new: Of the 46 current holders: 12 (26%) held >2 years, 25 held 1–2 years, and 9 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

Is it too late to buy Metagenomi Therapeutics Inc (MGX) following the 2026 Q1 hedge fund 13F filings?

As of today, MGX has moved -9.9% since the 2026 Q1 13F filing date (May 15, 2026), compared to +3.9% for the XLV sector ETF — an outperformance of -13.8%. Since the quarter end (March 31, 2026), MGX has gained -11.9% vs +2.8% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Metagenomi Therapeutics Inc (MGX)

Smart Money Signals — MGX

Selling streak — 4 quarters in a row

Below peak — only 60% of 3.0Y high

Outflows — 40% fewer funds vs a year ago

Heavy selling pressure — only 32% buying

Fewer new buyers each quarter (-6 vs last Q)

Mixed — 26% long-term, 20% new

Buying through price weakness — shares -2%, value -18%

Saturation — most institutions already know this story

Mixed cohorts — 7% veterans, 26% new entrants

Smaller funds dominant — 18% AUM from top-100

Institutional Sentiment Summary — MGX

Hedge Fund Ownership: MGX

Market Analysis: MGX

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: MGX

Is It Too Late to Buy Metagenomi Therapeutics Inc (MGX) Based on Hedge Fund 13F Filings?

Hedge Fund Positioning: MGX

Statistics: MGX

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q1)

Frequently Asked Questions — Metagenomi Therapeutics Inc (MGX)

Welcome to 13Foresight!